证券代码：688617 证券简称：惠泰医疗 公告编号：2025-062 深圳惠泰医疗器械股份有限公司 2025年第四次临时股东会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东会召开的时间：2025 年 12 月 25 日 （二） 股东会召开的地点：上海市徐汇区田林路 487 号宝石园 20 栋宝石大厦 22 楼会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 275 | | --- | --- | | 普通股股东人数 | 275 | | 2、出席会议的股东所持有的表决权数量 | 79,112,943 | | 普通股股东所持有表决权数量 | 79,112,943 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比例（%） | 62.4022 | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 62.4022 | ...

证券研究报告 | 2025年12月24日 ——医药生物行业2025年12月投资策略 推荐关注CXO板块 行业研究 · 行业投资策略 医药生物 投资评级：优于大市（维持评级） 证券分析师：陈曦炳 0755-81982939 chenxibing@guosen.com.cn S0980521120001 证券分析师：马千里 010-88005445 maqianli@guosen.com.cn S0980521070001 证券分析师：张超 0755-81982940 zhangchao4@guosen.com.cn S0980522080001 证券分析师：彭思宇 0755-81982723 pengsiyu@guosen.com.cn S0980521060003 证券分析师：陈益凌 021-60933167 chenyiling@guosen.com.cn S0980519010002 证券分析师：凌珑 021-60375401 linglong@guosen.com.cn S0980525070003 证券分析师：肖婧舒 0755-81982826 xiaojingshu@guosen.com.cn S0 ...

证券研究报告 | 2025年12月22日 医药生物周报（25 年第 49 周） 优于大市 政策端支持服务消费力度提升，关注医疗服务相关机会 本周医药板块表现弱于整体市场，化学制药跌幅居前。本周全部 A 股下 跌 0.07%（总市值加权平均），沪深 300 下跌 0.28%，中小板指下跌 0.80%，创业板指下跌 2.26%，生物医药板块整体下跌 0.14%，生物医 药板块表现弱于整体市场。分子板块来看，化学制药下跌 1.74%，生物 制品下跌 0.67%，医疗服务上涨 0.55%，医疗器械上涨 1.16%，医药商 业上涨 4.94%，中药上涨 0.17%。医药生物市盈率（TTM）37.07x，处 于近 5 年历史估值的 79.04%分位数。 近两年我国密集出台支持服务消费的政策，围绕"稳增长、扩内需、提 质量"，持续释放服务消费潜力。政策一方面从供给侧入手，通过扩大 和优化服务供给、放宽准入、提升服务质量与效率，推动医疗、养老、 文旅等重点领域升级；另一方面通过财政、金融和价格等工具，加大对 居民消费和服务业主体的支持，降低成本、激发需求。在此背景下，"犒 赏经济"成为新亮点，居民在满足基本需求后，更愿为健康 ...

｜2025年12月17日星期三｜ NO.1 公募年内自购规模同比增长超163% 据公募排排网统计数据，截至12月14日，今年以来公募基金净申购金额已达98.76亿元（剔除货币基 金），涉及基金产品1561只，净申购规模同比大幅增长163.08%。 公募业绩比较基准改革第一轮摸排在12月15日截止，基金公司向监管上报了摸排情况。 10月31日，证监会下发了《公开募集证券投资基金业绩比较基准指引》征求意见稿。据悉，征求意见稿 下发后，监管开启了第一轮摸排。此次摸排涵盖：有哪些产品要修改业绩比较基准、变更情况如何、需 要变更标准的产品规模及占比、基准变更是否与原基准差距较大、需要开持有人大会的产品占比等多方 面。 NO.3 QDII密集限购 据不完全统计，12月以来不到半个月时间，已有25只QDII基金宣布暂停申购或下调申购额度，部分产 品溢价率持续走高，溢价风险提示公告数量达到240条。 其中，富国纳斯达克指数ETF、华泰柏瑞纳斯达克100ETF等4只QDII基金，月内已提示风险高达16次。 从全市场来看，截至12月11日，全市场697只QDII基金（份额分开计算）中，共有437只基金处于限购 状态，占比超过六成 ...

会议资料 证券代码：688617 证券简称：惠泰医疗 深圳惠泰医疗器械股份有限公司 2025年第四次临时股东会 2025 年第四次临时股东会会议须知 为了维护全体股东的合法权益，确保公司股东会的正常秩序和议事效率，根 据《中华人民共和国公司法》（以下简称《公司法》）、《中华人民共和国证券 法》（以下简称《证券法》）、《上市公司股东会规则》以及《深圳惠泰医疗器 械股份有限公司章程》（以下简称《公司章程》）等相关规定，深圳惠泰医疗器 械股份有限公司（以下简称"公司"或"惠泰医疗"）特制订以下会议须知，请 出席股东会的全体人员遵照执行。 一、会议期间，全体出席人员应以维护股东的合法权益、保证股东会的正常 秩序和议事效率为原则，认真履行法定义务，自觉遵守股东会纪律，不得侵犯其 他股东的权益，以确保股东会的正常秩序。 2025 年 12 月 | 2025 | 年第四次临时股东会会议须知 | 2 | | --- | --- | --- | | 2025 | 年第四次临时股东会会议议程 | 4 | | 2025 | 年第四次临时股东会议案 | 6 | | 议案一 | 6 | | | 议案二 | | 20 | | 议案三 | ...

Core Insights - The report emphasizes the continuous improvement of the global competitiveness of Chinese innovative pharmaceutical companies, focusing on innovation from both "therapeutic areas" and "technology platforms" [5][6] - The growth of commercial health insurance premiums is expected to provide new payment sources for medical expenses, as the scale of commercial health insurance is projected to reach 977.4 billion yuan by 2024 [29][30] - The report identifies potential therapeutic areas such as metabolic diseases (e.g., weight loss), chronic diseases (e.g., hypertension, hyperlipidemia), and central nervous system diseases (e.g., Alzheimer's, Parkinson's) as key focus areas for innovation [5][38] - Emerging technology platforms like small nucleic acid drugs, radioactive drugs (RDC), and CAR-T therapies are highlighted as significant areas for investment [5][38] Market Review - As of November 15, 2025, the pharmaceutical sector has outperformed the market, with the pharmaceutical index rising by 22.09% compared to a 17.62% increase in the CSI 300 index, resulting in a 4.47 percentage point outperformance [11] - The chemical preparation sector showed the best performance, increasing by 40.52%, followed by medical services (+36.98%) and chemical raw materials (+25.34%) [20] - The overall PE valuation of the pharmaceutical sector is at 30.89 times, which is relatively low compared to historical averages, indicating potential for future growth [22][23] Innovative Drugs - The report notes that the growth of health expenditures in China, which reached 9.06 trillion yuan in 2023, is outpacing GDP growth, indicating a robust market for innovative drugs [26][27] - The analysis of multinational corporations (MNCs) reveals that innovation is a core competitive advantage, with companies like Eli Lilly and Novartis showing significant growth driven by innovative products in advanced technology fields such as GLP-1 and ADC [31][32] - The report highlights the strong sales performance of GLP-1 drugs, with Eli Lilly's Mounjaro generating $6.515 billion in revenue in Q3 2025, reflecting a 109% year-on-year increase [44] CXO and Upstream - The report indicates a slight increase in pharmaceutical financing, with a recovery in business development transactions and H-share IPOs, which is expected to stimulate innovation [5] - The demand for external CXO services is growing, particularly in emerging fields such as peptides and small nucleic acids, while internal CXO orders are also showing signs of recovery [5][39] Medical Devices - The domestic medical device market is currently under pressure due to policy impacts, but improvements are anticipated as companies continue to innovate and expand internationally [5] - The report suggests that the industry fundamentals are expected to improve, with a focus on companies like Mindray Medical and Microelectrophysiology [5][39]

证券代码：688617 证券简称：惠泰医疗 公告编号：2025-061 深圳惠泰医疗器械股份有限公司 关于回购股份事项的前十名股东及前十名无限售条 件股东持股情况的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 | 序号 | 股东名称 | 持股数量（股） | 占公司总股 本比例（%） | | --- | --- | --- | --- | | 1 | 深圳迈瑞科技控股有限责任公司 | 32,508,228 | 23.05 | | 2 | 成正辉 | 23,551,232 | 16.70 | | 3 | 香港中央结算有限公司 | 9,043,884 | 6.41 | | 4 | 珠海彤昇投资合伙企业（有限合伙） | 4,909,960 | 3.48 | | 5 | 招商银行股份有限公司－华夏上证科创板 50 成份交易型开放式指数证券投资基金 | 3,269,546 | 2.32 | | | 中国工商银行股份有限公司－易方达上证科创 | | | | 6 | | 3,065,891 | 2.17 | | 板 | 50 成份 ...

Investment Rating - The report maintains an "Outperform" rating for several companies in the innovative drug and medical device industry, including Jiangsu Heng Rui Medicine, Hansoh Pharmaceutical Group, 3SBio, Sichuan Kelun Pharmaceutical, and Jiangsu Nhwa Pharmaceutical [5][6][25]. Core Insights - The report emphasizes the high prosperity in innovative drugs and continues to recommend companies with innovative pipelines that are entering a volume increase phase, maintaining "Outperform" ratings for various Biopharma/Biotech companies [5][25]. - The National Healthcare Security Administration announced the 2025 insurance drug list, which added 114 drugs, including 50 innovative drugs, further validating insurance support for innovation and indicating promising domestic demand [26][27]. Summary by Sections 1. Continuous Recommendation of Innovative Drugs and Industry Chain - The report highlights the ongoing recommendation of innovative drugs and the industry chain, with a focus on companies expected to see a revaluation due to their innovative pipelines [5][25]. - Specific companies mentioned include WuXi AppTec, WuXi XDC Cayman, Hangzhou Tigermed Consulting, and leading medical equipment companies like Beijing Chunlizhengda Medical Instruments and Lepu Medical, all rated "Outperform" [5][25]. 2. Performance of A-Shares Pharmaceutical Sector - In the second week of December 2025, the A-Shares pharmaceutical sector underperformed the market, with the SW Pharma and Biotech index falling by 1.0% compared to a 0.3% decline in the SHCOMP [8][27]. - The report notes that the premium level of the pharmaceutical sector relative to all A-Shares is at a normal level, with a current relative premium rate of 69.8% [16][27]. 3. Performance of Hong Kong and U.S. Pharmaceutical Sectors - The Hong Kong stock pharmaceutical sector underperformed the market, with the Hang Seng Healthcare index falling by 2.3%, while the U.S. stock pharmaceutical sector outperformed, with the S&P 500 Healthcare Select Sector Index rising by 0.4% [28][27].

Investment Rating - The report maintains an "Overweight" rating for the innovative pharmaceutical and medical device industry chain [3][5][6]. Core Insights - The report emphasizes the continuous recommendation of innovative drugs and medical devices, highlighting the high growth potential in the innovative pharmaceutical sector. It maintains "Overweight" ratings for companies such as Heng Rui Medicine, Hansoh Pharmaceutical, and others, indicating a potential for value re-evaluation [3][5]. - The report notes that the National Medical Insurance Administration has officially announced the 2025 medical insurance drug catalog, which includes 114 new drugs, 50 of which are first-class innovative drugs. This adjustment is seen as a validation of the support for innovation in the healthcare sector [3][5]. - The A-share pharmaceutical sector underperformed the broader market in the second week of December 2025, with the SW Pharmaceutical Biotechnology index declining by 1.0% compared to a 0.3% drop in the Shanghai Composite Index [7][18]. Summary by Sections Section 1: Continuous Recommendation of Innovative Drugs and Medical Devices - The report highlights the sustained recommendation of innovative drugs and medical devices, with a focus on companies that are expected to see performance growth and value re-evaluation [5][6]. Section 2: A-share Pharmaceutical Sector Performance - In the second week of December 2025, the A-share pharmaceutical sector's performance was weaker than the overall market, ranking 16th among the primary industries [7][18]. Section 3: Hong Kong and US Market Performance - The report indicates that the Hong Kong pharmaceutical sector also underperformed, while the US pharmaceutical sector showed stronger performance compared to the broader market [18].

证券代码：688617 证券简称：惠泰医疗 公告编号：2025-060 深圳惠泰医疗器械股份有限公司 关于以集中竞价方式首次回购股份的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 本事项具体内容详见公司于 2025 年 12 月 10 日在上海证券交易所网站 （www.sse.com.cn）披露的《深圳惠泰医疗器械股份有限公司关于以集中竞价交易 方式回购股份方案暨回购报告书》（公告编号：2025-058）。 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2025/12/10，由董事会提议 | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 年 月 2025 9 10 | 12 | 日~2026 | 年 | 月 | 日 8 | | 预计回购金额 | 2亿元~2.5亿元 | | | | | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | | | | | | □用于转换公司可转债 | | | | | | | | ...